Clinuvel (ASX:CUV) share price gains 5% on FY21 profit boost

The ASX 200 biopharmaceutical company released its FY21 results this morning.

| More on:
Group of medical professionals high five

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Ltd (ASX: CUV) share price is gaining in early afternoon trade, up 4.76% to $29.70 per share at the time of writing.

Below we take a look at the ASX 200 biopharmaceutical company's financial results for the year ending 30 June, 2021 (FY21).

Clinuvel share price gains on FY21 results

  • Revenue and other income of $48.5 million, up from $33.9 million in FY20
  • Net profit after tax (NPAT) increased to $24.7 million from $15.1 million in FY20
  • Basic earnings per share (EPS) of 50 cents, up from 31 cents the prior year
  • Declared a dividend of 2.5 cents per share (cps), unfranked, the same as in FY20

What happened during the reporting period for Clinuvel?

In FY21, Clinuvel recorded its fifth consecutive year of positive cashflow, revenues and profit.

With an eye on growth, total expenses of $22.7 million were maintained, roughly in line with FY20's $22.4 million.

Over the course of the financial year, the company expanded its commercial distribution of its leading drug candidate SCENESSE in Europe and the United States. SCENESSE is intended to treat erythropoietic protoporphyria, a rare, genetic metabolic disorder.

Clinuvel also progressed with its research and development of other pharmaceuticals in its pipeline, being developed to treat a range of severe disorders.

There was also progress on the development of various non-prescription, dermatocosmetic products for people at high risk of exposure to ultraviolet (UV) and High Energy Visible (HEV) light.

The company had cash reserves of $82.7 million as at 30 June.

What did management say?

Commenting on the results, Clinuvel's chief financial officer Darren Keamy said:

The result has been driven by strong patient demand in Europe and in the USA, despite a challenging operating environment.

The progress in the US in the first full year of commercial operations is ahead of our planning, with over 40 Specialty Centers trained and accredited to administer SCENESSE and over 60 national and state private insurers reimbursing EPP patients' treatment.

Our US roll out, combined with ongoing demand in Europe, has helped deliver strong growth in revenues with only a relatively modest increase in overall expenses.

What's next for Clinuvel?

Looking ahead, Clinuvel said it's "committed to growing its commercial operations in Europe, the USA, Israel, and other countries".

The company is continuing to develop both prescription and non-prescription products to treat a range of medical issues, focused on repairing DNA damage.

It said its new divisional structure supports its growth plans. The new structure consists of: Pharmaceuticals; Healthcare Solutions; Communications, Branding & Marketing; and Manufacturing. Clinuvel says the new divisional structure is "underpinned" by its Research, Development & Innovation Centre, located in Singapore.

The Clinuvel share price is up 26% over the past 12 months.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

Up 74% in 2024, why is this ASX 200 stock rallying today?

Recurring revenues continue to grow.

Read more »

Man pointing at a blue rising share price graph.
Earnings Results

Guess which ASX All Ords share is soaring on 21% FY 2024 growth

Investors are piling into the ASX All Ords share today. Let’s find out why.

Read more »

Girl sliding down on snow with arms spread out.
Earnings Results

Elders shares on ice for a $475 million acquisition after profits plunge 55%

What on earth is going on with Elders shares today?

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Energy Shares

This ASX 200 mining stock just reported a 40% earnings jump

Investors appear pleased with this miner's performance during the first quarter.

Read more »

Business people discussing project on digital tablet.
Earnings Results

2 ASX All Ords shares surging over 10% on strong results

Investors are buying these shares in response to strong results this morning.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Earnings Results

Xero share price rockets to record high on explosive half-year growth

The tech star delivered another impressive half year results this morning.

Read more »

A man cheers after winning computer game while woman sitting next to him looks upset.
Earnings Results

2 high-flying ASX 200 gaming shares splitting ways today

Which gaming giant is winning the admiration of investors amid results?

Read more »

Male building supervisor wearing high vis vest and hard hat stands and smiles with his arms crossed at a building site
Industrials Shares

This $23 billion ASX 200 stock is surging 6% while the market sinks. Here's why

This ASX 200 stock is shrugging off the wider market sell down today and racing higher. But why?

Read more »